World-class
Scientific Advisory

Work with Richmond Pharmacology and trust your experience will be personal and truly strategic.

Professor David Oliveira - Professor of Renal Medicine (MD., F.R.C.P.)

Professor David Oliveira studied medicine at Cambridge University as well as Westminster Hospital Medical School where he qualified in 1979. Following five years in a variety of hospital medical jobs (with an emphasis on renal medicine) he completed a PhD in cellular immunology as an MRC Training Fellow at University College London.

In 1995, Professor Oliveira was appointed Foundation Professor of Renal Medicine/Honorary Consultant Nephrologist at St. George's University of London. In 2001 he was appointed Dean for Research & Development, also at St George's University of London, and Director of Research & Development for St George's Healthcare NHS Trust. Since June 2007 he has relinquished his Research & Development posts in order to become Course Director for the new combined MBBS course at St George's University of London. Professor Oliveira has also held a position as a Non-executive Director of Epsom and St Helier University Hospitals NHS Trust since December 2005.

His clinical research interests include trials of immunosuppressants (phase I and II work with Sirolimus in Cambridge, phase III work at St George's) and other aspects of treatment in renal medicine. Experimental research focuses on drug-induced autoimmunity, and the role and mechanisms of mast cell and Th2 cell activation in this process.

Some of Professor Oliveira's most important peer-reviewed publications include:

Oliveira DBG, Blackwell N, Virchis AE, Axelrod RA. T helper and T suppressor cells are restricted by the A and E molecules, respectively, in the F antigen system. Immunogenetics 1985; 22: 169-75.

Oliveira DBG, Nardi NB. Immune suppression genes control the anti-F antigen response in F1 hybrids and recombinant inbred sets of mice. Immunogenetics 1987; 26: 359-365.

Mathieson PW, Cobbold SP, Hale G, Clark MJ, Oliveira DBG, Lockwood CM, Waldmann H. Monoclonal antibody therapy in systemic vasculitis. N Engl J Med 1990; 323: 250-254.

Schofield JP, Vijayakumar RK, Oliveira DBG. Sequences of the mouse F protein alleles and identification of a T cell epitope. Eur J Immunol 1991; 21: 1235-1240.

Esnault VLM, Mathieson PW, Thiru S, Oliveira DBG, Lockwood CM. Autoantibodies to myeloperoxidase in Brown Norway rats treated with mercuric chloride. Lab Invest 1992; 67: 114-120.

Mathieson PW, Thiru S, Oliveira DBG. Mercuric chloride-treated Brown Norway rats develop widespread tissue injury including necrotizing vasculitis. Lab Invest 1992; 67: 121-129.

Mathieson PW, Thiru S, Oliveira DBG. Regulatory role of OX22+ T cells in mercury-induced autoimmunity in the Brown Norway rat. J Exp Med 1993; 177: 1309-1316.

Mathieson PW, Wurzner R, Oliveira DBG, Lachmann PJ, Peters DK.Complement-mediated adipocyte lysis by nephritic factor sera. J Exp Med 1993; 177: 1827-1831.

Zhang L, Jayne DRW, Zhao MH, Lockwood CM, Oliveira DBG. The distribution of MHC class II alleles in primary systemic vasculitis. Kidney Int 1995; 47: 294-298.

Oliveira DBG, Gillespie K, Wolfreys K, Mathieson PW, Qasim F, Coleman JW. Compounds that induce autoimmunity in the Brown Norway rat sensitize mast cells for mediator release and IL-4 expression. Eur J Immunol 1995; 25: 2259-2264.

Kiely PDW, Gillespie KM, Oliveira DBG. Oxpentifylline inhibits tumour necrosis factor?mRNA transcription and protects against arthritis in the mercuric chloride-treated Brown Norway rat. Eur J Immunol 1995; 25: 2899-2906.

Wolfreys K, Oliveira DBG. Alterations in intracellular reactive oxygen species generation and redox potential modulate mast cell function. Eur J Immunol 1997; 27: 297-306.

Kiely PDW, Pecht I, Oliveira DBG. Mercuric chloride-induced vasculitis in the Brown Norway rat: ab T-cell dependent and -independent phases: role of the mast cell. J Immunol 1997; 159: 5100-5106.

Oliveira DBG. Membranous nephropathy: an IgG4 mediated disease. Lancet 1998; 351: 670-671.

Wu Z, Turner DR, Oliveira DBG. Interleukin (IL)-4 gene expression upregulated by mercury in rat mast cells: a role of oxidant stress in IL-4 transcription. Int Immunol 2001; 13: 297-304.

Wu Z, MacPhee IAM, Oliveira DBG. Reactive oxygen species in the initiation of IL-4 driven autoimmunity as a potential therapeutic target. Curr Pharm Des 2004; 10: 899-913.

Vinen CS, Turner DR, Oliveira DBG. A role for ?? T cells in the resistant phase of the Brown Norway rat model of vasculitis. Clin Exp Immunol 2005; 140: 32-40.

Back to experts

Latest news

Upcoming Event

The 41st Annual Scientific Meeting of the Japanese Society of Clinical Pharmacology and Therapeutics (JSCPT)

4 – 5 December 2020
The 41st Annual Scientific meeting focuses on international collaboration in the pursuit of drug discovery and drug development.
View event

Marking a milestone for gene editing

November 10, 2020
We are pleased to share that Richmond Pharmacology, in partnership with Intellia Therapeutics and the Royal Free Hospital, have treated the first patient in a landmark CRISPR/Cas9 clinical trial of NTLA-2001
Read more

Richmond Pharmacology is delighted to confirm partnership with Intellia Therapeutics

October 20, 2020
Phase I study of Intellia Therapeutic’s NTLA-2001 for the treatment of hereditary transthyretin amyloidosis with polyneuropathy (hATTR-PN)
Read more

Richmond Pharmacology supports ReViral with the development of Sisunatovir

September 9, 2020
ReViral has confirmed the FDA has granted Fast Track designation to Sisunatovir.
Read more